Phase II Single-Arm Trial of Preemptive Prophylaxis With Long-Acting Recombinant Factor VIII Fc Fusion Protein, Eloctate, to Prevent Inhibitor Formation in Children With Severe Hemophilia A

Trial Profile

Phase II Single-Arm Trial of Preemptive Prophylaxis With Long-Acting Recombinant Factor VIII Fc Fusion Protein, Eloctate, to Prevent Inhibitor Formation in Children With Severe Hemophilia A

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 03 May 2017

At a glance

  • Drugs Efmoroctocog alfa (Primary)
  • Indications Haemophilia A
  • Focus Pharmacodynamics
  • Acronyms INHIBIT
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 27 Apr 2017 Planned initiation date changed from 1 Mar 2017 to 1 Mar 2018.
    • 21 Feb 2016 Planned End Date changed from 1 Mar 2022 to 1 Mar 2024, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top